Kondisetty Sandeep, Menon Krishnakumar N, Pooleri Ginil Kumar
1Department of Urology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ponekkara, Kochi, Kerala India.
2Center for Nanosciences and Molecular Medicine, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Ponekkara, Kochi, Kerala India.
Biomark Res. 2018 Jul 11;6:23. doi: 10.1186/s40364-018-0137-8. eCollection 2018.
Carcinogenesis is a multistep process which involves interplay between the tumour cells and the matrix proteins. This occurs by adherence between the tumour cells and proteins in the extracellular matrix. VHL mutation affects through the hypoxia inducible factor (HIF) and causes changes in various tissue proteins like VEGF, PDGF, TGF, Fibronectin and others. As not much literature is available, we aim to quantify the changes of fibronectin protein in renal cell carcinoma (RCC) tissue.
This Prospective unbalanced case control study was conducted over a period of 18 months from April 2016 to September 2017. The patients undergoing nephrectomy for the diagnosis of RCC were included in the study after obtaining written informed consent. Patients were excluded from study, if normal renal tissue could not be identified in the resected kidney and if the artery clamp time to retrieval of tissue was more than 30 min. Fibronectin protein is estimated in the tumour tissue by gel electrophoresis and western blotting which is compared with that of normal kidney tissue of the same kidney. Results have been expressed as absolute values with standard deviation and relative expression (RE).
Of the 21 patients analysed 15 showed an increase in fibronectin expression in the renal tumour tissue while 6 did not. The mean expression of Fibronectin protein has increased 1.5 times in the tumour tissue when compared with the normal tissue. The increase was 1.54 times in early tumours compared to 1.37 times in advanced tumours of RCC.
Fibronectin showed a 1.5 times increase in the tumour compared to normal. This increase is more in Stage 1&2 tumours when compared to the Stage 3&4 tumours.
肿瘤发生是一个多步骤过程，涉及肿瘤细胞与基质蛋白之间的相互作用。这通过肿瘤细胞与细胞外基质中的蛋白质粘附而发生。VHL突变通过缺氧诱导因子（HIF）产生影响，并导致多种组织蛋白如VEGF、PDGF、TGF、纤连蛋白等发生变化。由于相关文献不多，我们旨在量化肾细胞癌（RCC）组织中纤连蛋白的变化。
本前瞻性非平衡病例对照研究于2016年4月至2017年9月进行，为期18个月。在获得书面知情同意后，将因诊断为RCC而接受肾切除术的患者纳入研究。如果在切除的肾脏中无法识别正常肾组织，以及从组织获取到动脉夹闭时间超过30分钟，则将患者排除在研究之外。通过凝胶电泳和蛋白质印迹法估计肿瘤组织中的纤连蛋白，并与同一肾脏的正常肾组织进行比较。结果以绝对值、标准差和相对表达（RE）表示。
在分析的21例患者中，15例肾肿瘤组织中纤连蛋白表达增加，6例未增加。与正常组织相比，肿瘤组织中纤连蛋白的平均表达增加了1.5倍。早期肿瘤中的增加为1.54倍，而RCC晚期肿瘤中的增加为1.37倍。
与正常情况相比，肿瘤中纤连蛋白增加了1.5倍。与3期和4期肿瘤相比，1期和2期肿瘤中的增加更为明显。
